RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
A group of Hong Kong researchers have shown the viability of “liquid biopsy” early cancer screening in a large trial. Dennis Lo, PhD, the founder of Hong Kong cancer screening company Cirina, along with associates at Hong Kong University, conducted a three-year test among 20,000 men for nasopharyngeal cancer. 34 cases were discovered, and 71% of the cases were still at an early stage of development. The results were published in The New England Journal of Medicine. In June, Cirina merged into Grail, a California company that has raised $1 billion to develop early screening tests for cancer.
Source: ChinaBio Today
